PA
SPRY icon

Parallel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Parallel Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38
Closed -$478 – 3690
2025
Q1 		$478 Buy
38
+21
+124% +$253 ﹤0.01% 3243
2024
Q4 		$179 Buy
+17
New +$238 ﹤0.01% 3395
2023
Q4 		– Sell
-151
Closed -$571 – 3464
2023
Q3 		$571 Buy
+151
New +$991 ﹤0.01% 3081
2023
Q2 		– Sell
-45
Closed -$293 – 3511
2023
Q1 		$293 Sell
45
-863
-95% -$6.63K ﹤0.01% 3236
2022
Q4 		$7.75K Hold
908
– – ﹤0.01% 2137
2022
Q3 		$5K Hold
908
– – ﹤0.01% 2320
2022
Q2 		$4K Buy
+908
New +$3.17K ﹤0.01% 2378
2021
Q3 		– Sell
-415
Closed -$13K – 3256
2021
Q2 		$13K Hold
415
– – ﹤0.01% 1907
2021
Q1 		$18K Buy
415
+250
+152% +$11.8K ﹤0.01% 1652
2020
Q4 		$8K Buy
+165
New +$5.51K ﹤0.01% 1888

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parallel Advisors's SPRY Position: Q2 2025 in Review

Parallel Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 38 shares — an estimated $478 sold.

Parallel Advisors first reported a position in SPRY in Q4 2020 and held it in 10 quarters. The position peaked at $18K in Q1 2021. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • Parallel Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 38 ARS Pharmaceuticals shares in Q2 2025, an estimated $478.
  • Parallel Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Parallel Advisors's ARS Pharmaceuticals position peaked at $18K in Q1 2021.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.